This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -33.33% and 8.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Insulet (PODD) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.
Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Insulet (PODD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 250.00% and 3.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why the Earnings Surprise Streak Could Continue for Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Insulet (PODD) Up 5.1% Since Last Earnings Report?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff
by Zacks Equity Research
Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.
Insulet (PODD) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for GW Pharma (GWPH) This Earnings Season?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 50.00% and 1.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
by Zacks Equity Research
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
by Zacks Equity Research
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
by Zacks Equity Research
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
4 Top Stocks With the Power of Earnings Acceleration
by Tirthankar Chakraborty
Studies show that a majority of successful stocks see acceleration in earnings before a positive stock price movement.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.